Integrated Filing — IndAS



General information about company

Scrip Code 544184
NSE Symbol BOROSCI
MSEI Symbol NOTLISTED
ISIN INE02L001032
Name of company BOROSIL SCIENTIFIC LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 06-11-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 30-10-2025
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Multi segment
Description of single segment
Start date and time of board meeting 06-11-2025   15:30:00
End date and time of board meeting 06-11-2025   17:45:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2025 01-04-2025
B Date of end of reporting period 30-09-2025 30-09-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
1 Income
Revenue from operations 10,689.88 20,287.52
Other income 214.97 506.77
Total income 10,904.85 20,794.29
2 Expenses
(a) Cost of materials consumed 3,922.31 7,277.57
(b) Purchases of stock-in-trade 235.55 445.58
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (291.10) (400.59)
(d) Employee benefit expense 2,064.01 4,069.76
(e) Finance costs 22.63 61.00
(f) Depreciation, depletion and amortisation expense 481.46 969.08
(f) Other Expenses
1 Other Expenses 3,956.51 7,605.30
Total other expenses 3,956.51 7,605.30
Total expenses 10,391.37 20,027.70
3 Total profit before exceptional items and tax 513.48 766.59
4 Exceptional items 0.00 (661.31)
5 Total profit before tax 513.48 105.28
6 Tax expense
7 Current tax 308.38 308.38
8 Deferred tax (79.64) (66.88)
9 Total tax expenses 228.74 241.50
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 284.74 (136.22)
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 284.74 (136.22)
17 Other comprehensive income net of taxes (1.85) (3.35)
18 Total Comprehensive Income for the period 282.89 (139.57)
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent 289.27 (127.16)
Total profit or loss, attributable to non-controlling interests (4.53) (9.06)
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent 287.45 (130.45)
Total comprehensive income for the period attributable to owners of parent non-controlling interests (4.56) (9.12)
21 Details of equity share capital
Paid-up equity share capital 889.47 889.47
Face value of equity share capital 1 1
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 0.32 -0.14
Diluted earnings (loss) per share from continuing operations 0.32 -0.14
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 0.32 -0.14
Diluted earnings (loss) per share from continuing and discontinued operations 0.32 -0.14
24 Debt equity ratio 0 0
25 Debt service coverage ratio 0 0
26 Interest service coverage ratio 0 0
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) Notes on Unaudited Consolidated Financial Results for the quarter and half year ended 30th September, 2025: 1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 6th November, 2025. The Statutory Auditors of the Company have carried out a Limited Review of the above results. 2. Pursuant to exercise of the options issued under “Borosil Scientific Limited - Special Purpose Employee Stock Option Plan 2023”, the Company has made allotment of 1,122 Equity Shares and 13,747 Equity Shares, respectively of the face value of Re. 1/- each for the quarter and half year ended 30th September, 2025, which has resulted into increase of paid up Equity Share Capital by Rs. 0.01 lakhs and Rs. 0.14 lakhs, respectively and Securities Premium by Rs. 1.34 lakhs and Rs. 15.14 lakhs, respectively. 3. As informed earlier, the Company had introduced a Voluntary Retirement Scheme (VRS) for the eligible workers at its plant situated at Village Ambad, Nashik, Maharashtra . During the first quarter, the Company entered into a Memorandum of Settlement, with the Bhartiya Kamgar Sena (BKS), outlining the terms of final settlement under VRS. BKS is a trade union registered under Trade Union’s Act, 1926, representing the said eligible workers. The above settlement resulted total expenditure of Rs. 661.31 lakhs (including professional fees related to the above) for quarter ended 30th June, 2025 and half year ended 30th September, 2025 and shown as an exceptional item in the above results. 4. The figures for the corresponding previous period/year have been rearranged/ regrouped, wherever necessary, to make them comparable. For Borosil Scientific Limited (Formerly Known as Klass Pack Limited) Place: Mumbai Vinayak Patankar Date : 6th November, 2025 Whole-time Director & CEO (DIN 07534225)



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2025
Date of end of reporting period 30-09-2025
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Consolidated
Assets
1 Non-current assets
Property, plant and equipment 11,796.37
Capital work-in-progress 187.96
Investment property 0.00
Goodwill 6,219.37
Other intangible assets 455.36
Intangible assets under development 38.92
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 1.25
Trade receivables, non-current 0.00
Loans, non-current 11.03
Other non-current financial assets 236.08
Total non-current financial assets 248.36
Deferred tax assets (net) 501.90
Other non-current assets 806.49
Total non-current assets 20,254.73
2 Current assets
Inventories 10,323.97
Current financial asset
Current investments 10,805.47
Trade receivables, current 5,780.29
Cash and cash equivalents 793.23
Bank balance other than cash and cash equivalents 47.25
Loans, current 17.06
Other current financial assets 341.70
Total current financial assets 17,785.00
Current tax assets (net) 8.60
Other current assets 1,874.88
Total current assets 29,992.45
3 Non-current assets classified as held for sale 0.00
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 50,247.18
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 889.47
Other equity 39,555.66
Total equity attributable to owners of parent 40,445.13
Non controlling interest 12.39
Total equity 40,457.52
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 91.45
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities 0.00
Total non-current financial liabilities 91.45
Provisions, non-current 590.08
Deferred tax liabilities (net) 969.93
Deferred government grants, Non-current 0.00
Other non-current liabilities 0.00
Total non-current liabilities 1,651.46
Current liabilities
Current financial liabilities
Borrowings, current 795.49
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 881.98
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 2,438.99
Total Trade payable 3,320.97
Other current financial liabilities 2,402.81
Total current financial liabilities 6,519.27
Other current liabilities 889.81
Provisions, current 643.20
Current tax liabilities (Net) 85.92
Deferred government grants, Current 0.00
Total current liabilities 8,138.20
3 Liabilities directly associated with assets in disposal group classified as held for sale 0.00
4 Regulatory deferral account credit balances and related deferred tax liability 0.00
Total liabilities 9,789.66
Total equity and liabilites 50,247.18
Disclosure of notes on assets and liabilities Textual Information(1)



Text Block

Textual Information(1) Notes on Unaudited Consolidated Financial Results for the quarter and half year ended 30th September, 2025: 1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 6th November, 2025. The Statutory Auditors of the Company have carried out a Limited Review of the above results. 2. Pursuant to exercise of the options issued under “Borosil Scientific Limited - Special Purpose Employee Stock Option Plan 2023”, the Company has made allotment of 1,122 Equity Shares and 13,747 Equity Shares, respectively of the face value of Re. 1/- each for the quarter and half year ended 30th September, 2025, which has resulted into increase of paid up Equity Share Capital by Rs. 0.01 lakhs and Rs. 0.14 lakhs, respectively and Securities Premium by Rs. 1.34 lakhs and Rs. 15.14 lakhs, respectively. 3. As informed earlier, the Company had introduced a Voluntary Retirement Scheme (VRS) for the eligible workers at its plant situated at Village Ambad, Nashik, Maharashtra . During the first quarter, the Company entered into a Memorandum of Settlement, with the Bhartiya Kamgar Sena (BKS), outlining the terms of final settlement under VRS. BKS is a trade union registered under Trade Union’s Act, 1926, representing the said eligible workers. The above settlement resulted total expenditure of Rs. 661.31 lakhs (including professional fees related to the above) for quarter ended 30th June, 2025 and half year ended 30th September, 2025 and shown as an exceptional item in the above results. 4. The figures for the corresponding previous period/year have been rearranged/ regrouped, wherever necessary, to make them comparable. For Borosil Scientific Limited (Formerly Known as Klass Pack Limited) Place: Mumbai Vinayak Patankar Date : 6th November, 2025 Whole-time Director & CEO (DIN 07534225)



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-07-2025 01-04-2025
Date of end of reporting period 30-09-2025 30-09-2025
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
1 Scientific – Laboratory Glass & equipment and nProcess System 7,093.89 13,405.86
2 Glassware 3,391.03 6,614.68
3 Others 0.0020496 0.0026698
Total Segment Revenue 10,689.88 20,287.52
Less: Inter segment revenue 0.00 0.00
Revenue from operations 10,689.88 20,287.52
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
1 Scientific – Laboratory Glass & equipment and nProcess System 1,246.79 2,085.68
2 Glassware (415.60) (642.60)
3 Others 61.77 85.69
Total Profit before tax 892.96 1,528.77
i. Finance cost 22.63 61.00
ii. Other Unallocable Expenditure net off Unallocable income 356.85 1,362.49
Profit before tax 513.48 105.28
3 (Segment Asset - Segment Liabilities)
Segment Asset
1 Scientific – Laboratory Glass & equipment and nProcess System 20,086.92 20,086.92
2 Glassware 10,841.16 10,841.16
3 Others 306.88 306.88
Total Segment Asset 31,234.96 31,234.96
Un-allocable Assets 19,012.22 19,012.22
Net Segment Asset 50,247.18 50,247.18
4 Segment Liabilities
Segment Liabilities
1 Scientific – Laboratory Glass & equipment and nProcess System 5,821.34 5,821.34
2 Glassware 1,957.52 1,957.52
3 Others 46.77 46.77
Total Segment Liabilities 7,825.63 7,825.63
Un-allocable Liabilities 1,964.03 1,964.03
Net Segment Liabilities 9,789.66 9,789.66
Disclosure of notes on segments Textual Information(2)



Text Block

Textual Information(2) Note : As per Indian Accounting Standard 108 on ‘Operating Segment’ (Ind-AS 108), the Group has reported Segment information, as described below: Scientific – Laboratory Glass & equipment and Process System:- Comprising of items used in laboratories, production floor and research and development Glassware:- pharmaceutical primary packaging and domestic glassware items Others :- Comprising of Filter Paper etc. Unallocated:- Consists of income, expenses, assets and liabilities which can not be directly identified to any of the above segments.



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2025 01-04-2025
B Date of end of reporting period 30-09-2025 30-09-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Re-measurement gains / (losses) on defined benefit plans (2.48) (4.48)
Total Amount of items that will not be reclassified to profit and loss (2.48) (4.48)
2 Income tax relating to items that will not be reclassified to profit or loss (0.63) (1.13)
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income (1.85) (3.35)



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2025
B Date of end of reporting period 30-09-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Consolidated
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 105.28
Adjustments for reconcile profit (loss)
Adjustments for finance costs 61.00
Adjustments for decrease (increase) in inventories (670.61)
Adjustments for decrease (increase) in trade receivables, current 1,275.58
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets 47.77
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current 0.00
Adjustments for other financial assets, current 0.00
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current (159.60)
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 92.55
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 969.08
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 0.00
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 0.00
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains (16.72)
Adjustments for dividend income 0.00
Adjustments for interest income 16.17
Adjustments for share-based payments 119.77
Adjustments for fair value losses (gains) (327.16)
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow (36.32)
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items 47.68
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) 1,386.85
Net cash flows from (used in) operations 1,492.13
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 717.57
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 774.56
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 2,000.00
Other cash payments to acquire equity or debt instruments of other entities 1,900.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 52.55
Purchase of property, plant and equipment 1,008.25
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 12.57
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash (5.27)
Net cash flows from (used in) investing activities (848.40)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 15.28
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 0.00
Repayments of borrowings 525.91
Payments of lease liabilities 31.49
Dividends paid 0.00
Interest paid 62.12
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 138.92
Net cash flows from (used in) financing activities (465.32)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes (539.16)
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents (0.10)
Net increase (decrease) in cash and cash equivalents (539.26)
Cash and cash equivalents cash flow statement at beginning of period 1,332.37
Cash and cash equivalents cash flow statement at end of period 793.11





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Unaudited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 M/s. Chaturvedi & Shah LLP Yes 30-06-2026